Regeneron Pharmaceuticals (REGN) EBITDA Margin (2009 - 2026)

Regeneron Pharmaceuticals' EBITDA Margin history runs 18 years deep, the most recent figure standing at 18.35% for Q1 2026.

• In Q1 2026, EBITDA Margin fell 957.0% year-over-year to 18.35%; the TTM figure through Mar 2026 stood at 29.53% (down 316.0% YoY), while the FY2025 annual figure was 32.0%, up 42.0% from the prior year.
• EBITDA Margin was 18.35% for Q1 2026 at Regeneron Pharmaceuticals, down from 21.96% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 1659.2% in Q1 2022 to a low of 18.35% in Q1 2026.
• Historically, EBITDA Margin has averaged 197.66% across 5 years, with a median of 30.59% in 2023.
• The sharpest annual moves came in 2022 and 2023: EBITDA Margin jumped 161562 bps in 2022, then plunged 163153 bps in 2023.
• A 5-year view of EBITDA Margin shows it stood at 1233.4% in 2022, then plunged by 97 bps to 36.56% in 2023, then plunged by 39 bps to 22.42% in 2024, then retreated by 2 bps to 21.96% in 2025, then slipped by 16 bps to 18.35% in 2026.
• The last three EBITDA Margin figures came in at 18.35% (Q1 2026), 21.96% (Q4 2025), and 39.33% (Q3 2025), per Business Quant data.